Chongqing Precision Biotech Co., Ltd. (hereinafter referred to as the “Company”) was founded in 2016 as a high-tech enterprise established by a technical team led by Professor Qian Cheng, a renowned scientist in precision medicine. Taking gene editing and synthetic biology technologies as its core technological foundation, the Company focuses on the development and application of gene and cell therapeutics. It has grown into one of China’s leading enterprises in the CAR-T/NK field and is committed to becoming a global, innovative, and pioneering biopharmaceutical company.

The Company has established R&D collaboration and expert exchange mechanisms with 7 overseas institutions and 19 domestic universities, bringing together more than 20 experts and scholars and a high-caliber R&D team of over 300 professionals. It has established an Industrial Technology Research Institute, a Postdoctoral Research Workstation, and an Overseas Talent Workstation, and has been accredited as a Chongqing New High-end R&D Institution, Technology Innovation Center, Key Laboratory, and Engineering Research Center, among other innovation platforms.

As an enterprise driven by cutting-edge technological innovation, the Company masters key technologies in the cell therapy field, with more than 200 invention patents filed and patent portfolios deployed across developed countries and regions. The Company has advanced more than 10 CAR-T product pipelines targeting leukemia, lymphoma, multiple myeloma, gastrointestinal cancer, lung cancer, liver cancer, breast cancer, pancreatic cancer and other malignancies. To date, the Company has obtained four Class I biological new drug approvals for CAR-T cells and ten implied licenses for indications, making it the most innovative enterprise with the largest number of approved registered clinical pipelines in China. 

Its registered clinical trials are progressing smoothly and have achieved excellent efficacy data. The Company’s CAR-T therapy for pediatric leukemia became China’s first approved CAR-T drug product. Meanwhile, its CAR-T therapies for solid tumors such as colorectal cancer and gastric cancer achieved the first registered clinical approvals in China in these indications, placing the Company at the forefront of global clinical development and drug registration. At the same time, the Company is actively advancing cutting-edge technologies including point-of-care manufacturing, in vivo CAR-T, oncolytic viruses, gene therapeutics, and mRNA technologies.

Currently, the Company has built a 18,000-square-meter fully integrated platform covering the entire upstream and downstream of cell therapeutics development, and has been granted the first CAR-T Drug Manufacturing License in Western China, making it one of only a few companies in China holding such a qualification.The Company is also establishing a regional cell manufacturing center in the core area of Chongqing Western Science City. Included in the National Development and Reform Commission (NDRC)’s national “Major Strategic Projects” program and supported by dedicated policy and funding initiatives, the project is expected to deliver an annual production capacity of 100,000 batches of cell products and intermediates. Based on the Chongqing manufacturing base, the facility will support the cell preparation needs of the Company’s clinical centers nationwide. By 2028, the Company aims to launch 3-5 Class I national CAR-T drugs and achieve sales revenue exceeding RMB 10 billion.